AI-Enabled Multiomics Platform
Next Generation Precision-Medicine Tools
Two complementary solutions, spatial multiomics and transcriptomics, powered by AI to guide cancer diagnosis and treatment.
Spatial and Proteomics Based Solutions
Our methodology includes the use of common conductive slides with analytes study while keeping protein integrity and uses consecutively the following technologies:
Mass spectrometry imaging (MSI)
By Matrix Assisted Laser Desorption Ionization (MALDI-MSI) for fast spatial omics pre-screening of proteins and/or metabolites.
Laser Capture Microdissection (LMD)
Enables the selection of specific tissue areas allowing subsequent molecular identification.
LC-MS/MS
Liquid chromatography coupled to tandem mass spectrometry, high-resolution peptide identification and label-free quantification.
Artificial Intelligence
Algorithms providing full analysis reports of tumor tissues and patient profiles with therapeutic options rankings.
Transcriptomics Based Solutions
A New Biomarker Analysis Technique
We've developed a complementary biomarker analysis solution that brings a new level of precision to cancer diagnostics and treatment selection.
Seamless Integration
Our solution can be integrated into existing diagnostic and e-Health platforms.
Better Data
Standardized gene expression analysis ensures more relevant results.
Targeted Treatments
Identifies deregulated pathways to guide effective therapy selection.
How it Works
"Our normalized expression score provides more predictive insights into treatment response than raw expression data, enabling truly personalized cancer care."
For Hospitals & Clinics
Rosetta Omics platform can be used by oncologists, clinicians, and pathologists to better diagnose, stratify and rank first-line treatment options for cancer patients.
Our platform offers physicians easy access to spatial omics for lipids and metabolites pre-screening as well as high-resolution proteomics and genomics profiling, from one unique tissue slide per patient.
Our products combine a biostatistical process and AI tools providing full analysis reports of the tissue area or region of interest (list of proteins and metabolites, label-free quantification) and patient profile (significant biomarkers, tumor profile, and more).
For Pharma & Biotechs
Rosetta Omics platform can provide Pharma & Biotechs with additional methods and data to identify biomarkers of clinical interest.
Thanks to this approach, which stands out from the problems of antibody specificities, we can identify both known and novel biomarkers of clinical interest, allowing faster diagnostic validation, new therapeutic strategies and combinations, and better tumor classification for pharmaceutical companies.